دورية أكاديمية
Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials.
| العنوان: | Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials. |
|---|---|
| المؤلفون: | Fadlullah MZH; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.; Department of Biomedical Informatics, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Lin CN; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.; Department of Biomedical Informatics, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Coleman S; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.; Department of Biomedical Informatics, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Young A; Department of Pathology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Naqash AR; Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, The University of Oklahoma, Oklahoma City, OK, USA., Hu-Lieskovan S; Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Tan AC; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.; Department of Biomedical Informatics, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. |
| المصدر: | The oncologist [Oncologist] 2024 May 03; Vol. 29 (5), pp. 415-421. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2022- : Oxford : Oxford University Press Original Publication: Dayton, Ohio : AlphaMed Press, c1996- |
| مواضيع طبية MeSH: | Immune Checkpoint Inhibitors*/adverse effects , Immune Checkpoint Inhibitors*/therapeutic use , Data Mining* , Neoplasms*/drug therapy , Clinical Trials as Topic* , Drug-Related Side Effects and Adverse Reactions*/epidemiology, Humans ; Big Data ; Databases, Factual/statistics & numerical data |
| مستخلص: | Purpose: Immune checkpoint inhibitors (ICIs) have significantly improved the survival of patients with cancer and provided long-term durable benefit. However, ICI-treated patients develop a range of toxicities known as immune-related adverse events (irAEs), which could compromise clinical benefits from these treatments. As the incidence and spectrum of irAEs differs across cancer types and ICI agents, it is imperative to characterize the incidence and spectrum of irAEs in a pan-cancer cohort to aid clinical management. Design: We queried >400 000 trials registered at ClinicalTrials.gov and retrieved a comprehensive pan-cancer database of 71 087 ICI-treated participants from 19 cancer types and 7 ICI agents. We performed data harmonization and cleaning of these trial results into 293 harmonized adverse event categories using Medical Dictionary for Regulatory Activities. Results: We developed irAExplorer (https://irae.tanlab.org), an interactive database that focuses on adverse events in patients administered with ICIs from big data mining. irAExplorer encompasses 71 087 distinct clinical trial participants from 343 clinical trials across 19 cancer types with well-annotated ICI treatment regimens and harmonized adverse event categories. We demonstrated a few of the irAE analyses through irAExplorer and highlighted some associations between treatment- or cancer-specific irAEs. Conclusion: The irAExplorer is a user-friendly resource that offers exploration, validation, and discovery of treatment- or cancer-specific irAEs across pan-cancer cohorts. We envision that irAExplorer can serve as a valuable resource to cross-validate users' internal datasets to increase the robustness of their findings. (© The Author(s) 2024. Published by Oxford University Press.) |
| References: | J Med Toxicol. 2021 Oct;17(4):411-424. (PMID: 33826117) Chest. 2017 Aug;152(2):271-281. (PMID: 28499515) Annu Rev Med. 2021 Jan 27;72:313-330. (PMID: 32886542) Assay Drug Dev Technol. 2016 Dec;14(10):557-566. (PMID: 27631620) Blood. 2021 Mar 25;137(12):1669-1678. (PMID: 33067632) N Engl J Med. 2015 Jul 2;373(1):23-34. (PMID: 26027431) Histopathology. 2020 Jan;76(2):233-243. (PMID: 31361907) Front Immunol. 2023 Aug 21;14:1229823. (PMID: 37671166) N Engl J Med. 2022 Jan 6;386(1):24-34. (PMID: 34986285) N Engl J Med. 2016 Nov 10;375(19):1823-1833. (PMID: 27718847) Oncologist. 2018 Jul;23(7):849-851. (PMID: 29666298) Ann Surg Oncol. 2005 Dec;12(12):1005-16. (PMID: 16283570) J Clin Endocrinol Metab. 2014 Nov;99(11):4078-85. (PMID: 25078147) Int J Cancer. 2019 Aug 1;145(3):639-648. (PMID: 30653255) J Emerg Med. 2018 Oct;55(4):489-502. (PMID: 30120013) Cancer Immunol Immunother. 2021 Oct;70(10):3041-3053. (PMID: 33877385) Immunotargets Ther. 2017 Oct 10;6:73-82. (PMID: 29067284) Ann Oncol. 2017 Oct 01;28(10):2377-2385. (PMID: 28945858) J Clin Oncol. 2017 Dec 20;35(36):4050-4056. (PMID: 28837405) Diabetes. 2018 Aug;67(8):1471-1480. (PMID: 29937434) Nephrol Dial Transplant. 2022 Aug 22;37(9):1598-1608. (PMID: 33374000) AAPS J. 2021 Mar 7;23(2):39. (PMID: 33677681) Nat Med. 2018 Nov;24(11):1655-1661. (PMID: 30297911) Nat Rev Dis Primers. 2020 May 7;6(1):38. (PMID: 32382051) |
| معلومات مُعتمدة: | R01 DE030508 United States DE NIDCR NIH HHS; R01DE030508 United States NH NIH HHS |
| فهرسة مساهمة: | Keywords: data mining; immune checkpoint inhibitor; immune-related adverse events; irAExplorer |
| المشرفين على المادة: | 0 (Immune Checkpoint Inhibitors) |
| تواريخ الأحداث: | Date Created: 20240208 Date Completed: 20240503 Latest Revision: 20240520 |
| رمز التحديث: | 20240520 |
| مُعرف محوري في PubMed: | PMC11067818 |
| DOI: | 10.1093/oncolo/oyae012 |
| PMID: | 38330451 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1549-490X |
|---|---|
| DOI: | 10.1093/oncolo/oyae012 |